神经营养因子
神经科学
医学
阿尔茨海默病
脑源性神经营养因子
转基因小鼠
鼻腔给药
信使核糖核酸
神经营养素
老化
转基因
治疗方法
疾病
生物信息学
认知
神经退行性变
免疫学
长时程增强
认知功能衰退
中枢神经系统
神经保护
精密医学
下调和上调
小RNA
核糖核酸
退行性疾病
免疫系统
作者
Maria Bergamasco,Hannah A. Scarborough,Anna Ponta,Teleri Clark,Scott B. Cohen,Lipin Loo,Kazuma Fujikake,Rebecca Carr,R. M. Damian Holsinger,G. Gregory Neely
摘要
Messenger RNA (mRNA) therapeutics have rapidly emerged as a transformative approach for treating a range of health challenges. Accelerated by the success of mRNA-lipid nanoparticle (LNP) vaccines during the COVID-19 pandemic, this platform holds promise beyond immunisation for the transient expression of therapeutic proteins in targeted tissues. Despite this promise, non-invasive delivery of mRNA-encoded cargo to the brain remains a challenge, as most peptide drugs do not pass the blood-brain barrier. Here, we present the development of an intranasal mRNA-LNP therapeutic that drives production of neurotrophic factors in the nasal epithelium and delivery of the encoded protein to the brain. As a proof of concept, we demonstrate that intranasal delivery of mRNA encoding the neurogenic factor BDNF (Brain Derived Neurotrophic Factor) enhances memory performance in both aged mice and a transgenic mouse model of Alzheimer's disease. This approach offers a promising platform for delivering therapeutic proteins to the brain and opens new avenues for treating age-related and neurodegenerative disorders.
科研通智能强力驱动
Strongly Powered by AbleSci AI